Article
Oncology
Matteo Serenari, Enrico Prosperi, Marc-Antoine Allard, Michele Paterno, Nicolas Golse, Andrea Laurenzi, Rene Adam, Matteo Ravaioli, Daniel Cherqui, Matteo Cescon
Summary: This study demonstrates that the time interval between hepatic resection (HR) and secondary liver transplantation (SLT) is a key factor in predicting complications after liver transplantation (LT), without affecting hepatocellular carcinoma (HCC)-related death.
Review
Radiology, Nuclear Medicine & Medical Imaging
Giuseppe Mamone, Settimo Caruso, Mariapina Milazzo, Giorgia Porrello, Ambra Di Piazza, Giovanni Gentile, Vincenzo Carollo, Francesca Crino, Gianluca Marrone, Gianvincenzo Sparacia, Luigi Maruzzelli, Roberto Miraglia, Salvatore Gruttadauria
Summary: Liver transplantation provides the best survival benefit for hepatocellular carcinoma (HCC) patients who cannot undergo resection. The Milan criteria have been developed to select suitable candidates for transplantation, aiming to improve survival and reduce the risk of HCC recurrence. However, up to 20% of cases experience HCC recurrence after transplantation, posing a significant challenge due to poor prognosis. Various extended criteria have been proposed to accommodate the increasing demand for organs and the associated higher risk of recurrence. Radiologists need to be aware of the possibility of HCC recurrence involving multiple organs after transplantation. Understanding the location and radiologic appearance of recurrent HCC is crucial for choosing the most appropriate therapy.
INSIGHTS INTO IMAGING
(2023)
Article
Oncology
Wei Li, Haitao Xiao, Hong Wu, Xuewen Xu, Yange Zhang
Summary: This study compared the long-term outcomes of liver transplantation (LT) and liver resection (LR) for patients with stage I and II hepatocellular carcinoma (HCC). The results showed that LT provided significant prognostic advantages in overall survival and disease-free survival compared to LR. Increasing the LT rate may lead to better long-term survival, but caution is needed when selecting LT for special populations like elderly patients due to similar outcomes with LR.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo
Summary: Recurrence of hepatocellular carcinoma after liver transplantation is a major concern, with poor prognosis and uncertainty in management. There is currently lack of specific surveillance strategy and sufficient data to support immunosuppressive drugs and adjuvant therapy.
Article
Medicine, General & Internal
Indah Jamtani, Kwang-Woong Lee, Yunhee Choi, YoungRok Choi, Jeong-Moo Lee, Eui-Soo Han, Kwangpyo Hong, Gyu-Seong Choi, Jong Man Kim, Nam-Joon Yi, Suk Kyun Hong, Jeik Byun, Su Young Hong, Sanggyeun Suh, Jae-Won Joh, Kyung-Suk Suh
Summary: This study aimed to develop a tailored prediction model of HCC-specific survival after transplantation, validated internally and externally. By combining multiple risk factors, the model showed good accuracy in predicting HCC-specific survival tailored for patients undergoing transplantation. The calculated SALT predictor provided accurate information on expected survival rates based on risk scores and specific characteristics.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Caroline P. Lemoine, Omid Madadi-Sanjani, Claus Petersen, Christophe Chardot, Jean de Ville de Goyet, Riccardo Superina
Summary: This study evaluated surgeons' practices in pediatric liver surgery and made recommendations for the management of children needing liver surgery. The findings suggest that pediatric liver surgery should be performed by specialized pediatric surgeons and centralized in regional centers of excellence.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Mun Chae Choi, Eun-Ki Min, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim, Deok-Gie Kim
Summary: This study investigated the use of antiplatelet drugs in preventing hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). The findings suggest that antiplatelet therapy does not impact HCC recurrence or HCC-specific mortality when used after LT.
Review
Biochemistry & Molecular Biology
Zurabi Lominadze, Kareen Hill, Mohammed Rifat Shaik, Justin P. Canakis, Mohammad Bourmaf, Cyrus Adams-Mardi, Ameer Abutaleb, Lopa Mishra, Kirti Shetty
Summary: The emerging field of immuno-oncology has brought exciting developments in the treatment of hepatocellular carcinoma (HCC), with potential benefits in liver transplantation settings. Immune therapeutic agents have shown promise in down-staging advanced HCCs pre-transplant and managing recurrent HCC post-transplant. This review discusses optimal regimens in the context of liver transplantation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Ramin Raul Ossami Saidy, Maximilian Paul Postel, Michael Johannes Pfluger, Wenzel Schoening, Robert Oellinger, Safak Gul-Klein, Moritz Schmelzle, Frank Tacke, Johann Pratschke, Dennis Eurich
Summary: Liver transplantation is a curative option for hepatocellular carcinoma, but recurrence after transplant can lead to limited survival. This study found that reducing immunosuppression after recurrence diagnosis can improve patient survival, suggesting the need for further investigation in this area.
Review
Gastroenterology & Hepatology
Sang Jin Kim, Jong Man Kim
Summary: Liver transplantation is an effective treatment for hepatocellular carcinoma, but some patients still experience recurrence after transplantation. Prediction models for HCC recurrence after transplantation have been published, but a standard has not been established. This review summarizes the latest prediction models for HCC recurrence after liver transplantation, focusing on radiologic, serologic, and pathologic factors, and includes studies on living donor and deceased donor transplantation.
CLINICAL AND MOLECULAR HEPATOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Yoshihisa Takahashi, Erdenetsogt Dungubat, Hiroyuki Kusano, Toshio Fukusato
Summary: Nonalcoholic fatty liver disease (NAFLD) refers to excessive fat accumulation in the livers of patients without a history of alcohol abuse. It can progress to liver cirrhosis and hepatocellular carcinoma (HCC). Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly increasing in incidence globally and is becoming an increasingly important cause of HCC.
Review
Gastroenterology & Hepatology
Leana Frankul, Catherine Frenette
Summary: Downstaging treatment is crucial for patients with unresectable hepatocellular carcinoma who are not eligible for liver transplantation, but severe organ shortage limits its broader application. Debate over the optimal treatment protocol and assessment method for downstaging treatment is pushing the boundaries of liver transplantation candidate selection.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2021)
Article
Surgery
Leigh Anne Dageforde, Neeta Vachharajani, Parissa Tabrizian, Vatche Agopian, Karim Halazun, Erin Maynard, Kristopher Croome, David Nagorney, Johnny C. Hong, David Lee, Cristina Ferrone, Erin Baker, William Jarnagin, Alan Hemming, Gabriel Schnickel, Shoko Kimura, Ronald Busuttil, Jessica Lindemann, Sander Florman, Matthew L. Holzner, Rami Srouji, Marc Najjar, Lavanya Yohanathan, Jane Cheng, Hiral Amin, Charles A. Rickert, Ju Dong Yang, Joohyun Kim, Jennifer Pasko, William C. Chapman, Maria B. Majella Doyle
Summary: Through a multicenter collaboration study, liver transplantation for cHCC-CCA within Milan criteria showed similar overall survival to HCC, with a higher chance of cure.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
(2021)
Article
Gastroenterology & Hepatology
Soon Kyu Lee, Jeong Won Jang, Heechul Nam, Pil Soo Sung, Hee Yeon Kim, Jung Hyun Kwon, Sung Won Lee, Do Seon Song, Chang Wook Kim, Myeong Jun Song, Ho Joong Choi, Young Kyoung You, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Summary: Sorafenib shows better outcomes in patients with liver transplantation (LT) compared to those without LT, likely due to smaller intrahepatic HCC and preserved hepatic function in LT recipients. Multiple subgroup analyses and propensity-score matching confirm the superior efficacy of sorafenib in the LT setting.
HEPATOLOGY INTERNATIONAL
(2021)
Review
Biochemistry & Molecular Biology
Lukasz Masior, Michal Grat
Summary: Hepatocellular carcinoma is a common indication for liver transplantation, but ischemia-reperfusion injury during the process can impact graft function and oncological outcomes. Strategies to manage IRI include pharmacotherapy, liver preconditioning, and machine perfusion. Efforts to shorten ischemic times and improve organ allocation pathways are still under development.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)